Viatris's and Biocon's Semglee is the first biosimilar "interchangeable" insulin drug to receive approval from the FDA.
Cost-related medication non-compliance, mounting political pressure, and the safety profile of Semglee were the major factors.
The approval should help Viatris to snag a couple hundred million dollars of annual revenue away from Sanofi's Lantus.

Search form

You are here